Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.

Burger R, Guidi M, Calpini V, Lamoth F, Decosterd L, Robatel C, Buclin T, Csajka C, Marchetti O.

J Antimicrob Chemother. 2018 Dec 1;73(12):3413-3422. doi: 10.1093/jac/dky370.

PMID:
30304491
2.

Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy.

Isla A, Rodríguez-Gascón A, Trocóniz IF, Bueno L, Solinís MA, Maynar J, Sánchez-Izquierdo JA, Pedraz JL.

Clin Pharmacokinet. 2008;47(3):173-80.

PMID:
18307371
3.

Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements.

Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodríguez AH, Pontes C, Calvo G, Torres A, Martín-Loeches I.

Antimicrob Agents Chemother. 2015 Sep;59(9):5520-8. doi: 10.1128/AAC.00712-15. Epub 2015 Jun 29.

5.

Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function.

Usman M, Frey OR, Hempel G.

Eur J Clin Pharmacol. 2017 Mar;73(3):333-342. doi: 10.1007/s00228-016-2172-4. Epub 2016 Dec 13.

PMID:
27966034
6.

Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.

Tsai D, Stewart P, Goud R, Gourley S, Hewagama S, Krishnaswamy S, Wallis SC, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2016 Nov;48(5):542-546. doi: 10.1016/j.ijantimicag.2016.08.015. Epub 2016 Sep 29.

PMID:
27771187
7.

Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.

Ulldemolins M, Vaquer S, Llauradó-Serra M, Pontes C, Calvo G, Soy D, Martín-Loeches I.

Crit Care. 2014 Jun 23;18(3):227. doi: 10.1186/cc13938. Review.

8.

Maximally effective dosing regimens of meropenem in patients with septic shock.

Sjövall F, Alobaid AS, Wallis SC, Perner A, Lipman J, Roberts JA.

J Antimicrob Chemother. 2018 Jan 1;73(1):191-198. doi: 10.1093/jac/dkx330.

PMID:
28961812
9.

Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation of clinical trial simulations.

Nehus EJ, Mizuno T, Cox S, Goldstein SL, Vinks AA.

J Clin Pharmacol. 2016 Mar;56(3):291-7. doi: 10.1002/jcph.601. Epub 2015 Sep 21.

PMID:
26222329
10.

Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model.

Minichmayr IK, Roberts JA, Frey OR, Roehr AC, Kloft C, Brinkmann A.

J Antimicrob Chemother. 2018 May 1;73(5):1330-1339. doi: 10.1093/jac/dkx526.

PMID:
29425283
11.

Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?

Udy AA, Lipman J, Jarrett P, Klein K, Wallis SC, Patel K, Kirkpatrick CM, Kruger PS, Paterson DL, Roberts MS, Roberts JA.

Crit Care. 2015 Jan 30;19:28. doi: 10.1186/s13054-015-0750-y.

12.

Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution.

Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J.

J Antimicrob Chemother. 2009 Jul;64(1):142-50. doi: 10.1093/jac/dkp139. Epub 2009 Apr 27.

PMID:
19398460
13.
14.

Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.

Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavijitkul T, Tangkitwanitjaroen K, Sukarnjanaset W, Jullangkoon M, Samaeng M.

Antimicrob Agents Chemother. 2015;59(6):2995-3001. doi: 10.1128/AAC.04166-14. Epub 2015 Mar 9.

15.

Population Pharmacokinetics and Pharmacodynamic Target Attainment of Meropenem in Critically Ill Young Children.

Cies JJ, Moore WS 2nd, Enache A, Chopra A.

J Pediatr Pharmacol Ther. 2017 Jul-Aug;22(4):276-285. doi: 10.5863/1551-6776-22.4.276.

16.

Are Standard Dosing Regimens of Ceftriaxone Adapted for Critically Ill Patients with Augmented Creatinine Clearance?

Ollivier J, Carrié C, d'Houdain N, Djabarouti S, Petit L, Xuereb F, Legeron R, Biais M, Breilh D.

Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02134-18. doi: 10.1128/AAC.02134-18. Print 2019 Mar.

PMID:
30602511
17.

Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.

Kees MG, Minichmayr IK, Moritz S, Beck S, Wicha SG, Kees F, Kloft C, Steinke T.

J Clin Pharmacol. 2016 Mar;56(3):307-15. doi: 10.1002/jcph.600. Epub 2015 Sep 18.

PMID:
26222202
18.

Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.

Hanberg P, Öbrink-Hansen K, Thorsted A, Bue M, Tøttrup M, Friberg LE, Hardlei TF, Søballe K, Gjedsted J.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02390-17. doi: 10.1128/AAC.02390-17. Print 2018 May.

19.

Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patients.

Cojutti P, Maximova N, Pea F.

Antimicrob Agents Chemother. 2015 Sep;59(9):5535-41. doi: 10.1128/AAC.00787-15. Epub 2015 Jun 29.

20.

Cefepime dosing regimens in critically ill patients receiving continuous renal replacement therapy: a Monte Carlo simulation study.

Chaijamorn W, Charoensareerat T, Srisawat N, Pattharachayakul S, Boonpeng A.

J Intensive Care. 2018 Sep 12;6:61. doi: 10.1186/s40560-018-0330-8. eCollection 2018.

Supplemental Content

Support Center